Related Experiment Video
Updated: Jul 29, 2026

Applying Stereotactic Injection Technique to Study Genetic Effects on Animal Behaviors
Published on: May 10, 2015
Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses
L J Brandes1, R J Arron, R P Bogdanovic
1Department of Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Abstract:
Tricyclic antidepressants, such as amitriptyline (Elavil), and the nontricyclic agent, fluoxetine (Prozac), bind to growth-regulatory intracellular histamine receptors, associated with anti-estrogen binding sites in microsomes and nuclei. The prototype anti-estrogen binding site/intracellular histamine receptor ligand, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl, inhibits normal cell proliferation in vitro but stimulates tumor growth in vivo. Because of their structural similarity to N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl, we carried out studies to determine whether amitriptyline and fluoxetine stimulate tumor growth and/or development in rodents at concentrations relevant to the treatment of human depression (equivalent human dose range, approximately 100-150 mg/day for amitriptyline and approximately 20-80 mg/day for fluoxetine). All experiments were performed blinded. In studies of growth stimulation of transplantable syngeneic tumors, groups of mice were inoculated s.c. with C-3 fibrosarcoma cells or given i.v. or s.c. injections of B16f10 melanoma cells, followed 24 h later by daily i.p. injections of saline, amitriptyline, or fluoxetine. Tumor latency (fibrosarcoma), aggregate tumor weight (s.c. injected melanoma), or time to death from pulmonary metastasis (i.v. injected melanoma) was determined; drug-induced stimulation of DNA synthesis in C-3 fibrosarcoma cells in vitro was correlated with tumor growth acceleration in vivo. In a mammary carcinogenesis model, the effects of chronic saline, amitriptyline, or fluoxetine administration on the rate and frequency of development of mammary tumors in rats fed dimethylbenzanthracene (DMBA) were compared. Eight of 20 amitriptyline- or fluoxetine-treated mice developed fibrosarcoma tumors by day 5, as compared to none of 20 saline controls (P less than 0.002). Similarly, 20 of 21 DMBA-treated rats receiving the antidepressant drugs developed 33 mammary tumors by week 15 as compared to 5 tumors in 4 of 7 DMBA-treated rats receiving saline (P less than 0.001). For both models, tumor latency decreased 30-40% and, in the DMBA model, tumor frequency increased greater than 2-fold in the antidepressant-treated rats as compared to controls. Stimulation of fibrosarcoma growth in vivo correlated with a corresponding bell-shaped drug-induced increase in DNA synthesis in vitro. While the median time to death from pulmonary metastases did not differ among groups given i.v. injections of melanoma cells, a significant (P less than 0.01) stimulation of growth of s.c. injected melanoma was observed in mice receiving the antidepressants.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
Tricyclic antidepressants and fluoxetine may stimulate tumor growth. Studies show these antidepressants accelerated tumor development in rodents, suggesting potential risks in cancer patients.
Area of Science:
- Pharmacology
- Oncology
- Cell Biology
Background:
- Tricyclic antidepressants (e.g., amitriptyline) and fluoxetine interact with intracellular histamine receptors.
- These receptors are linked to anti-estrogen binding sites, and a related compound stimulates tumor growth in vivo.
- The structural similarity suggests a potential for antidepressants to influence tumor development.
Purpose of the Study:
- To investigate whether amitriptyline and fluoxetine stimulate tumor growth and/or development in rodent models.
- To assess these effects at concentrations relevant to human therapeutic doses for depression.
Main Methods:
- Rodent models were used, including syngeneic tumor transplants (fibrosarcoma, melanoma) and a mammary carcinogenesis model (DMBA-induced).
- Animals received daily injections of saline, amitriptyline, or fluoxetine.
- Tumor latency, weight, metastasis, and DNA synthesis were measured; experiments were blinded.
Main Results:
- Amitriptyline and fluoxetine significantly increased the incidence and accelerated the development of fibrosarcoma and mammary tumors.
- Tumor latency decreased by 30-40%, and tumor frequency more than doubled in antidepressant-treated groups.
- Antidepressants stimulated DNA synthesis in fibrosarcoma cells in vitro, correlating with accelerated tumor growth in vivo.
Conclusions:
- Amitriptyline and fluoxetine demonstrate tumor-growth-stimulating properties in rodent models.
- These findings suggest a potential risk of antidepressants influencing tumor progression.
- Further research is warranted to understand the clinical implications for cancer patients undergoing antidepressant treatment.

